search
Back to results

Incidence of TNS After Intrathecal Lidocaine v.s Bupivacaine

Primary Purpose

Orthopedic Disorder, Leg Injuries

Status
Unknown status
Phase
Not Applicable
Locations
Canada
Study Type
Interventional
Intervention
Lidocaine
Bupivacaine Hcl 0.5% Inj_#2
Sponsored by
McGill University Health Centre/Research Institute of the McGill University Health Centre
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Orthopedic Disorder

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • ASA I-III male and female patients aged between 18 to 80 years old, who will receive spinal anesthesia for surgeries lasting less than one hour.

Exclusion Criteria:

  • Patients younger than 18 years old.
  • ASA physical status >3.
  • Immunosuppression or high risk of infection.
  • Contraindications to receiving spinal anesthesia (e.g. coagulation impairment).
  • Patients with psychosis
  • Patients with preexisting back pain.
  • Patients with cognitive impairment
  • Allergies to local anesthetics, analgesics or any medication used in the study.
  • Patients with chronic regular opioid usage
  • Presence of preexisting neurological symptoms.

Sites / Locations

  • Montreal General HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

Intrathecal Lidocaine

Intrathecal Bupivacaine

Arm Description

Patients will receive spinal anesthesia in the sitting position under strict sterile conditions in the operating room. Using a median or paramedian approach, the spinal needle will be inserted into the L2-3 or L3-4 interspace to reach the subarachnoid space. After confirming the space by free flow of CSF, 60 mg of isobaric preservative-free Lidocaine 2% will be injected. Sedation using propofol infusion (50-100 mcg/kg/min) and fentanyl (0.5-1 mcg/kg) will be given throughout the procedure as required.

Patients will receive spinal anesthesia in the sitting position under strict sterile conditions in the operating room. Using a median/paramedian approach, the spinal needle will be inserted into the L2-3 or L3-4 interspace to reach the subarachnoid space. After confirming the space by free flow of CSF, 6 mg of 0.5% isobaric bupivacaine will be injected. Sedation using propofol infusion (50-100 mcg/kg/min) and fentanyl (0.5-1 mcg/kg) will be given throughout the procedure as required.

Outcomes

Primary Outcome Measures

Transient Neurological Symptoms
To determine the incidence of TNS following the use of intrathecal Lidocaine as compared with Bupivacaine
Transient Neurological Symptoms
To determine the incidence of TNS following the use of intrathecal Lidocaine as compared with Bupivacaine

Secondary Outcome Measures

Transient Neurological Symptoms
To determine the incidence of TNS following the use of intrathecal Bupivacaine
Transient Neurological Symptoms
To determine the incidence of TNS following the use of either intrathecal Lidocaine and Bupivacaine in patients operated in the lithotomy position

Full Information

First Posted
February 19, 2019
Last Updated
March 1, 2019
Sponsor
McGill University Health Centre/Research Institute of the McGill University Health Centre
search

1. Study Identification

Unique Protocol Identification Number
NCT03862287
Brief Title
Incidence of TNS After Intrathecal Lidocaine v.s Bupivacaine
Official Title
Is Lidocaine Really Guilty? A Prospective, Randomized, Double Blind Comparison of the Incidence of TNS After Intrathecal Lidocaine Administration vs. Intrathecal Bupivacaine in Patients Undergoing Spinal Anesthesia
Study Type
Interventional

2. Study Status

Record Verification Date
March 2019
Overall Recruitment Status
Unknown status
Study Start Date
November 1, 2018 (Actual)
Primary Completion Date
December 2019 (Anticipated)
Study Completion Date
December 2019 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
McGill University Health Centre/Research Institute of the McGill University Health Centre

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This study will look into the incidence of Transient neurological symptoms (TNS) after the intrathecal use of lidocaine in comparison to intrathecal Bupivacaine.
Detailed Description
Ever since the introduction of Spinal anesthesia in 1898 by the German surgeon August Bier, the approach gained wide acceptance by the anesthesia community 1. Since that time, the technique has evolved to accommodate a wide variety of surgical procedures, making it one of the most common regional anesthesia modalities used. The advancement of the anesthesia field has led to the advancement of the technique it self, specially the drugs used in it. A wide range of local anesthetics has been introduced after the initial successful intrathecal use of cocaine. Starting with amylocaine, and later with the introduction of various local anesthetics such as procaine, 2-chloroprocaine, lidocaine, tetracaine, mepivacaine, prilocaine, bupivacaine, with ropivacaine and levobupivacaine being introduced last. Many of these drugs have fallen out of favour due to various reasons, with Lidocaine, procaine, mepivacaine, ropivacaine and bupivacaine still being used in clinical practice 2. The choice of the local anesthetic used depends on many factors such as the duration of the operation, the type of surgery and the degree of motor blockade desired. With the advancement of surgery and the increase in day surgical cases, a need for a fast acting, short in duration local anesthetic that allows fast recovery and early discharge has emerged. Of all the local anesthetic drugs available, Lidocaine is one of the drugs that fulfills these needs. Common complications associated with the use of this technique include headache (5%), backache (11%), hypotension, bradycardia, nausea and vomiting (20%), urinary retention, hypothermia and transient neurological syndrome (TNS). More serious complications include total spinal, infection (meningitis/ encephalitis) and epidural hematoma (<1 in 150,000). On the other hand, complications related to receiving General Anesthesia for the same procedure are similar, with higher chances of nausea and vomiting or airway problems. TNS is defined as back pain and/or dysesthesia radiating bilaterally to the legs or buttocks after total recovery from spinal anesthesia, manifesting within 24 hours after the surgery and typically lasting less than a week. The etiology of TNS is unknown. Possible contributing factors to the development of TNS include sciatic nerve stretching causing neural ischemia, vasoconstriction of spinal cord arteries, patient positioning, direct needle injury and pooling of local anesthetic in the sacral region. The pathophysiology of TNS is unknown, and there is no specific lab test to diagnose this complication. Treatment of TNS, includes bed rest, administration of nonsteroidal anti inflammatory drugs and sometimes the addition of an opioid is needed 3. All local anesthetics have been shown to cause TNS, with lidocaine appearing to have the greatest risk. The first reported case of TNS after the single shot administration of 5% hyperbaric lidocaine was published by Schneider and colleagues in 1993 4, which was confirmed later by several other studies 5-9. The reported incidence of TNS after the administration of lidocaine ranges from 10%-40% 10-13. In a more resent study done by F. Salazar et al. the incidence of TNS with lidocaine was reported to be 2.5%, much lower than what was previously described in the literature 14. Furthermore, in an internal audit done at the MGH looking at all spinal anesthesia cases performed by Dr. Asenjo in the past two years, TNS incidence was found to be 2.7%, far less than what the literature describes, and correlates more with what F. Salazar et al. found in their study. We want to clarify this discrepancy in the incidence of TNS with lidocaine since this is a very inexpensive agent, with a short to intermediate duration of action and readily available world wide. With this purpose we have designed a randomized controlled trial to test the hypothesis that the incidence of TNS after spinal anesthesia with lidocaine is much lower than what was previously described in the literature. This trial will also look at the natural course of the symptoms of TNS.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Orthopedic Disorder, Leg Injuries

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantOutcomes Assessor
Allocation
Randomized
Enrollment
160 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Intrathecal Lidocaine
Arm Type
Active Comparator
Arm Description
Patients will receive spinal anesthesia in the sitting position under strict sterile conditions in the operating room. Using a median or paramedian approach, the spinal needle will be inserted into the L2-3 or L3-4 interspace to reach the subarachnoid space. After confirming the space by free flow of CSF, 60 mg of isobaric preservative-free Lidocaine 2% will be injected. Sedation using propofol infusion (50-100 mcg/kg/min) and fentanyl (0.5-1 mcg/kg) will be given throughout the procedure as required.
Arm Title
Intrathecal Bupivacaine
Arm Type
Active Comparator
Arm Description
Patients will receive spinal anesthesia in the sitting position under strict sterile conditions in the operating room. Using a median/paramedian approach, the spinal needle will be inserted into the L2-3 or L3-4 interspace to reach the subarachnoid space. After confirming the space by free flow of CSF, 6 mg of 0.5% isobaric bupivacaine will be injected. Sedation using propofol infusion (50-100 mcg/kg/min) and fentanyl (0.5-1 mcg/kg) will be given throughout the procedure as required.
Intervention Type
Drug
Intervention Name(s)
Lidocaine
Intervention Description
See arm description.
Intervention Type
Drug
Intervention Name(s)
Bupivacaine Hcl 0.5% Inj_#2
Intervention Description
See arm description.
Primary Outcome Measure Information:
Title
Transient Neurological Symptoms
Description
To determine the incidence of TNS following the use of intrathecal Lidocaine as compared with Bupivacaine
Time Frame
Day 1
Title
Transient Neurological Symptoms
Description
To determine the incidence of TNS following the use of intrathecal Lidocaine as compared with Bupivacaine
Time Frame
Day 3
Secondary Outcome Measure Information:
Title
Transient Neurological Symptoms
Description
To determine the incidence of TNS following the use of intrathecal Bupivacaine
Time Frame
Day 1 and day 3 postoperative
Title
Transient Neurological Symptoms
Description
To determine the incidence of TNS following the use of either intrathecal Lidocaine and Bupivacaine in patients operated in the lithotomy position
Time Frame
Day 1 and day 3 postoperative

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: ASA I-III male and female patients aged between 18 to 80 years old, who will receive spinal anesthesia for surgeries lasting less than one hour. Exclusion Criteria: Patients younger than 18 years old. ASA physical status >3. Immunosuppression or high risk of infection. Contraindications to receiving spinal anesthesia (e.g. coagulation impairment). Patients with psychosis Patients with preexisting back pain. Patients with cognitive impairment Allergies to local anesthetics, analgesics or any medication used in the study. Patients with chronic regular opioid usage Presence of preexisting neurological symptoms.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Juan F Asenjo
Phone
5149341934
Ext
43273
Email
jfasenjog@yahoo.com
Facility Information:
Facility Name
Montreal General Hospital
City
Montreal
State/Province
Quebec
ZIP/Postal Code
H3A 1A1
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
JF Asenjo, MD
Phone
514) 934-1934
Ext
43261
Email
jfasenjog@yahoo.com
First Name & Middle Initial & Last Name & Degree
JF Asenjo, MD

12. IPD Sharing Statement

Plan to Share IPD
Yes

Learn more about this trial

Incidence of TNS After Intrathecal Lidocaine v.s Bupivacaine

We'll reach out to this number within 24 hrs